

Enterprise Pharmacy and Therapeutics Committee Meeting
Call in number 646-876-9923 Meeting ID 831-139-3271
January 31st, 2022
5:00PM-7:00PM CST

Pre-register at jplante1@amerihealthcaritasla.com prior to the meeting

<u>Subject</u>	<u>Presenter</u>
1. Call to Order	B. Himmelstein
2. Conflict of Interest Disclosures	S. Cherian
3. Enterprise P&T Charter and Conflict of Interest Training	S. Cherian
4. BCC Positive Changes and PA Criteria Updates	C. Meny
5. Review and approval of October P&T	S. Cherian
6. Old Business	PerformRx
A. Agents for Graft Versus Host Disease	p. 118
B. VEGF Inhibitors for Ophthalmic Conditions	p. 120
C. Hepatitis C	p. 124
D. Step Therapy Exception.....	p. 136
E. New COVID Treatments	p. 137
F. Reblozyl	p. 139
G. ACNH Ondansetron Limits.....	p. 141
H. ACNH Opioid Limits.....	p. 143
I. ACNH PDL PA Criteria Updates	p. 145
J. ACDE PDL PA Changes.....	p. 163
K. BCC Allergenic Extracts PA criteria	p. 164
7. New Business	PerformRx
A. Anti-CD19 CAR-T Immunotherapies.....	p. 166
B. LAI Antipsychotics Specialty Update	p. 172
C. Synagis	p. 173
D. Testosterone	p. 177
8. Drug Reviews:	PerformRx
A. Therapeutic Class:	
1. First Generation Antihistamines.....	p. 180
2. Skeletal Muscle Relaxants.....	p. 202
3. New Cardiovascular Drugs	p. 212

4. Oral Iron Prep	p. 224
5. Antitussives and Expectorants	p. 240
6. Calcitonin Gene-Related Peptide Receptor Antagonists	p. 248
B. Single Products:	PerformRx
1. Methergine	p. 256
2. Tavneos	p. 262
3. Phexxi	p. 272
4. Opzelura	p. 278
5. Limvarli	p. 292
9. New Products	PerformRx
10. Prior Authorization Criteria Review:	PerformRx
A. Prior Authorization Criteria Annual Review:	
1. Adrenal Enzyme Inhibitors for Cushing's Disease	p. 311
2. Agents to Treat Constipation	p. 313
3. Alpha-1 Proteinase Inhibitors (Human)	p. 317
4. Benlysta	p. 321
5. Blincyto	p. 323
6. Glycopyrrolate	p. 327
7. Growth Hormone (GH) for Growth Failure or GH Deficiency	p. 329
8. SHSC – Long-Acting Opioid Containing Products	p. 337
9. Levalbuterol for Inhalation	p. 340
10. Non-Preferred Inhaled Corticosteroid/Beta Agonist Combination Inhalers for Asthma and Chronic Obstructive Pulmonary Disease (COPD)	p. 342
11. Ocaliva	p. 344
12. Proprotein Convertase Subtilisin/kexin 9 (PCSK9) Inhibitors	p. 346
13. Proton Pump Inhibitors	p. 351
14. ACNH – Buprenorphine	p. 357
15. Hemlibra	p. 359
16. BCC - IV Prostacyclins for PAH	p. 361
17. BCC – Lemtrada	p. 363
18. ACDE - Antipsychotics in Members under 18	p. 364
19. ACDE - Hepatitis C	p. 366
20. ACDE - Retinoic Acid Derivatives	p. 369
21. ACDE - Medications for Use in ADHD Treatment for Members 21 and Older	p. 370
22. ACDE – Opioid Use Disorder Treatment	p. 371
23. ACDE – Lidocaine Patch	p. 374
B. Prior Authorization Criteria Annual Review without Clinical Changes	
1. Amifampridine	p. 376

2. Anti-Parkinson's Agents for OFF Episodes	p. 378
3. Botulinum Toxins A&B	p. 380
4. Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators	p. 382
5. Dendritic Cell Tumor Peptide Immunotherapy (Provenge).....	p. 384
6. Diclegis	p. 386
7. Emflaza.....	p. 388
8. SHSC - Opioid Dependence Agents	p. 390
9. SHSC - Short Acting Opioid Containing Products for Naïve Members.....	p. 392
10. Hyaluronic Derivatives	p. 395
11. Juxtapid	p. 397
12. Naglazyme.....	p. 399
13. Natpara	p. 400
14. Second Generation Antihistamines.....	p. 402
15. Specialty Biological Agents for Polyarticular Juvenile Idiopathic Arthritis.....	p. 404
16. Specialty Biological Agents for Systemic Juvenile Idiopathic Arthritis.....	p. 406
17. Transthyretin-mediated Amyloidosis Agents	p. 408
18. AHDC - Opioid Containing Products	p. 414
19. AHDC - Hemophilia Factor VIII	p. 417
20. ACDE - Bleeding Disorder Blood Products	p. 419
21. ACDE – Latuda.....	p. 420
22. KF/AHC/CHC - Compound Products	p. 421
 C. New Prior Authorization Criteria	
1. Phenoxybenzamine	p. 423
2. Dojolvi	p. 424

11. Recalls

PerformRx

12. Adjourn

B. Himmelstein

*****NEXT MEETING: May 2nd, 2022*****